The thread of life Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (1040)	2/7/2007 11:02:18 AM
From: Mike McFarland	of 1336

Poking around at Sosei, I don't see anything too interesting yet, but I might as well paste this stuff here... Chizuko Koseki is head of the drug reprofiling platform of Sosei the-scientist.com (name was misspelled in the article) --- Sosei has signed DRP® partnership agreements with 30 biotech companies to date representing leading profiling technologies. Drug Reprofiling Platform® (DRP®) sosei.com --- From KineMed April 2005 PR "KineMed will screen numerous molecules provided by the library of Sosei's Drug Reprofiling Platform(R) (DRP(R)) using KineMed's proprietary in vivo KineMarker(TM) assays." --- Sosei’s Unique Business Model, Drug Reprofiling Platform® (DRP®) – Chizuko Koseki, Sosei Company –Drug Reprofiling Platform®(DRP®) is a unique business model established by Sosei in 1999. Sosei secures rights forcompounds from Japanese pharmaceutical companies to identify new therapeutic uses or to improve the efficacy intreating the original indication(s). Usually development of the compounds for original indications) has been halted by the originating pharmaceutical company for various reasons but not serious toxicity. Sosei also collaborates with innovative biotechnology companies who have unique technologies that can profile compounds to identify newtherapeutic uses. Sosei’s DRP business model is based on a risk sharing approach. Exclusive rights become only available to profiling companies if a new “hit” is made which leads to new patent filings covering a potential new indication or other line extension for the compound. Sosei then shares rights in the compound with the profiling partner and the originator of the compound. The DRP model can thus make a product development opportunity outof a “halted” project for the profiling partners, Sosei and the originators. Further development work is planned andundertaken according to the level of interest of the parties involved and may involve out licensing rights to other pharmaceutical firms. The projects can also be added to Sosei’s own portfolio. The four years of experience inmanaging the DRP model have been very encouraging with three projects already emerging and entering phase II.Chizuko will introduce DRP’s value and role in Sosei’s business. westorg.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next